Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Abstract Text:

Junji Kato,Koji Miyanishi,Masayoshi Kobune,Tokiko Nakamura,Kohichi Takada,Rishu Takimoto,Yutaka Kawano,Sho Takahashi,Minoru Takahashi,Yasushi Sato,Tetsuji Takayama,Yoshiro Niitsu,Junji Kato,Koji Miyanishi,Masayoshi Kobune,Tokiko Nakamura,Kohichi Takada,Rishu Takimoto,Yutaka Kawano,Sho Takahashi,Minoru Takahashi,Yasushi Sato,Tetsuji Takayama,Yoshiro Niitsu,

BACKGROUND: We have previously demonstrated that in patients with chronic hepatitis C (CHC), iron depletion improves serum alanine aminotransferase (ALT) levels as well as hepatic oxidative DNA damage. However, it has not been determined whether continuation of iron depletion therapy for CHC favorably influences its progression to hepatocellular carcinoma (HCC). METHODS: We conducted a cohort study on biopsy-proven CHC patients with moderate or severe liver fibrosis who failed to respond to previous interferon (IFN) therapy or had conditions for which IFN is contradicted. Patients were divided into two groups: subjects in group A (n = 35) underwent weekly phlebotomy (200 g) until they reached a state of mild iron deficiency, followed by monthly maintenance phlebotomy for 44-144 months (median, 107 months), and they were advised to consume a low-iron diet (5-7 mg iron/day); group B (n = 40) comprised CHC patients who declined to receive iron depletion therapy. RESULTS: In group A, during the maintenance phase, serum ALT levels decreased to less than 60 IU/l in all patients and normalized (<40 IU/l) in 24 patients (69%), whereas in group B no spontaneous decrease in serum ALT occurred. Hepatocarcinogenesis rates in groups A and B were 5.7% and 17.5% at the end of the fifth year, and 8.6% and 39% in the tenth year, respectively. Multivariate analysis revealed that iron depletion therapy significantly lowered the risk of HCC (odds ratio, 0.57) compared with that of untreated patients (P = 0.0337). CONCLUSIONS: Long-term iron depletion for CHC patients is a promising modality for lowering the risk of progression to HCC.

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Publishing Authors By Initials

J Kato,K Miyanishi,M Kobune,T Nakamura,K Takada,R Takimoto,Y Kawano,S Takahashi,M Takahashi,Y Sato,T Takayama,Y Niitsu,J Kato,K Miyanishi,M Kobune,T Nakamura,K Takada,R Takimoto,Y Kawano,S Takahashi,M Takahashi,Y Sato,T Takayama,Y Niitsu,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of gastroenterology

VOLUME: 42

Page Numbers: 830-6

Journal Abbreviation: J. Gastroenterol.

ISSN: 0944-1174

DAY: 15

MONTH: 10

YEAR: 2007

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9430794

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.

AFFILIATION: Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1, West-16, Sapporo 060-8543, Japan.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C Related Publications

• A Phase I Trial of Arterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Unresectable Advanced Pancreatic Cancer after Vascular Supply Distribution via Superselective Embolization.
• Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis.
• Adenoviral vector-mediated transfer of the Indian hedgehog gene modulates lymphomyelopoiesis in vivo.
• Apoptosis Supercedes Necrosis in Mitochondrial DNA-Depleted Jurkat Cells by Cleavage of Receptor-Interacting Protein and Inhibition of Lysosomal Cathepsin.
• Case report of a focal nodular hyperplasia-like nodule present in cirrhotic liver.
• Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
• Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.
• Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.
• Point mutation of aldehyde dehydrogenase-2 gene in mutant strains of Long-Evans rats.
• Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.
• Successful radiotherapy in a patient with primary rectal mucosa-associated lymphoid tissue lymphoma without the API2-MALT1 fusion gene: A case report and review of the literature.
• Successful treatment of autoimmune pancreatitis complicated with autoimmune thrombocytopenia and interstitial pneumonia by prednisolone.
• Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate.
• Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
• Undifferentiated pleomorphic sarcoma detected in the descending colon: report of a case.
• [A Case of Hepatosplenic gd T-Cell Lymphoma Associated Hemophagocytic Syndrome.]
• [A comment on the qualification of the visiting nurse: a proposal for the requirement of training lasting several months following certain clinical experience]
• [An Advanced Metastatic Breast Cancer Patient Successfully Treated with Combination Therapy Including Docetaxel, Doxorubicin and Cyclophosphamide (TAC) as Salvage Therapy.]
• [Anemia in patient with cancer]
• [Cyclic thrombocytopenia complicated with Sjögren syndrome and the mechanism of periodic platelet count fluctuation]
• [Malignant lymphoma. Physiopathology and therapy. 3. Diffuse large B-cell lymphoma]
• [Problems and results of surgical treatment of interventricular septal defect with pulmonary hypertension]
• [Suturing of the fibrous ring in mitral insufficiency]